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ABSTRACT 
OBJECTIVES: The Common Data Elements (CDE) project was developed by the National 
Institute of Neurological Disorders and Stroke (NINDS) to provide clinical researchers with tools 
to improve data quality and allow for harmonization of data collected in different research 
studies. CDEs have been created for several neurological diseases; the aim of this project was to 
develop CDEs specifically curated for mitochondrial disease (Mito) to enhance clinical research. 
METHODS: Nine working groups (WGs), composed of international mitochondrial disease 
experts, provided recommendations for Mito clinical research. They initially reviewed existing 
NINDS CDEs and instruments, and developed new data elements or instruments when needed. 
Recommendations were organized, internally reviewed by the Mito WGs, and posted online for 
external public comment for a period of eight weeks. The final version was again reviewed by all 
WGs and the NINDS CDE team prior to posting for public use. 
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RESULTS: The NINDS Mito CDEs and supporting documents are publicly available on the 
NINDS CDE website (https://commondataelements.ninds.nih.gov/), organized into domain 
categories such as Participant/Subject Characteristics, Assessments, and Examinations. 
CONCLUSION: We developed a comprehensive set of CDE recommendations, data 
definitions, case report forms (CRFs), and guidelines for use in Mito clinical research. The 
widespread use of CDEs is intended to enhance Mito clinical research endeavors, including 
natural history studies, clinical trial design, and data sharing. Ongoing international collaboration 
will facilitate regular review, updates and online publication of Mito CDEs, and support 
improved consistency of data collection and reporting. 
 
Keywords: clinical outcome measures; clinical research; common data elements; computerized 
report forms; mitochondrial disease 
 
 
 
 
 
 
 
 
Introduction 
The Common Data Element (CDE) project began in 2005 as part of an initiative by the National 
Institute of Neurological Disorders and Stroke (NINDS) to assist NINDS-funded investigators in 
the collection of neuroscientific clinical trial research data in a standardized and consistent 
fashion (Grinnon et al 2012). The CDEs are content standards that can be applied to various data 
collection models and are intended to be dynamic and evolve over time, as indicated by research 
advances. The CDE project is not a database – rather it is a collection of metadata and data 
standards, used to facilitate sharing and combination of data across studies as a means of data 
comparison and analysis. Its goal is to develop common definitions for clinical research data as 
well as the creation of standardized Case Report Forms (CRFs) and instruments. The goals of the 
NINDS CDE Project are to: 1) Disseminate standards for data collection from participants 
enrolled in neurological disease studies; 2) Create easily accessible tools for investigators to 
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collect study data. These tools should be especially helpful to new investigators and others 
working with limited budgets; 3) Encourage focused and simplified data collection to reduce 
burden on investigators and practice-based clinicians to facilitate their participation in clinical 
research; 4) Improve data quality while controlling cost by providing uniform data descriptions 
and tools across NINDS-funded clinical studies (Grinnon et al 2012). As the CDEs were being 
developed, the number of clinical trials for patients with mitochondrial disease also rose, 
highlighting the value and urgency of such tools to be developed. 
To date, the NINDS CDE database has developed metadata with data standards and instruments 
for 18 neurological diseases. In the case of mitochondrial disease, CDE validation can be 
complex due to the broad array of mechanisms causing mitochondrial diseases and dysfunction. 
This paper reviews the process by which the Mito WGs, an international group of mitochondrial 
disease experts, developed CDEs to be used in the field of mitochondrial disease research. The 
draft Mito CDEs were reviewed by the external mitochondrial disease research community prior 
to finalization and posted to the NINDS CDE website in 2015. The WG participant rosters may 
be found on the NINDS CDE web page (https://commondataelements.ninds.nih.gov/). 
  
Background 
Brief description of Mitochondrial Diseases 
Mitochondrial diseases (also known as disorders of oxidative phosphorylation (OXPHOS), 
mitochondrial respiratory chain diseases, mitochondrial cytopathies,and mitochondriopathies) 
are a group of disorders caused by genetic defects that directly or indirectly affect the OXPHOS 
system, the major energy generating pathway in cells (Chinnery 2014; DiMauro and Schon 
2003). The prevalence of mitochondrial disease is difficult to establish for many reasons, 
including their clinical and genetic heterogeneity, challenges in establishing a precise genetic 
diagnosis, and complexities in patient ascertainment and referral. The prevalence of all 
pathogenic mutations in both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) is at least 
1:4,300 (Gorman et al 2015). Approximately 15% (DiMauro and Schon 2003) of mitochondrial 
disorders are caused by inherited germline mutations in the mtDNA. Mitochondrial disorders can 
also be caused by mutations in over 250 nDNA genes (Gorman et al 2016) and dysfunction can 
be acquired due to adverse environmental effects of drugs and infections (Niyazov 2016). Those 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
disorders resulting from inherited nDNA or mtDNA gene mutations that have an effect on the 
structure or function of the OXPHOS system are termed “primary mitochondrial diseases” 
(Parikh et al 2015). Some mitochondrial disorders affect a single organ, but many involve 
multiple organ systems and can present with a bewildering array of multisystem phenotypes, 
including neurologic symptoms and myopathies, visual and hearing loss, as well as cardiac, 
endocrine, gastrointestinal, hepatic and/or renal dysfunction (Chinnery 2014). Some well-
characterized multisystem clinical syndromes have now been recognized as being mitochondrial 
diseases. Primary inherited mitochondrial diseases encompass hundreds of individual genetic 
disorders that are heterogeneous and frequently multisystemic, yet share common disease 
mechanisms and overlapping clinical phenotypes. One challenge, not necessarily unique to 
mitochondrial disorders, is that there may be great variation between individuals with the same 
mutation. With respect to mtDNA mutations (e.g., Mitochondrial encephalomyopathy, lactic 
acidosis and stroke-like episodes (MELAS) mutation), variation may depend on the percentage 
heteroplasmy (mutation load) in any given tissue and the number of tissues harboring the 
mutation, adding to the wide phenotypic spectrum and variable disease severity. A 
comprehensive overview can be found on the North American Mitochondrial Disease 
Consortium (NAMDC) website (https://www.rarediseasesnetwork.org/cms/namdc/Learn-
More/Disorder-Definitions).  
Marked variability remains in the diagnostic approaches, treatment, and management of 
mitochondrial diseases (Parikh et al 2015).  Conducting large-scale clinical trials for patients 
with mitochondrial diseases is difficult, given their extreme clinical variability, biochemical and 
genetic heterogeneity, and the rarity of each etiology or subtype. Despite all of these constraints, 
several clinical trials for mitochondrial diseases are underway, none of which are using any 
mitochondrial disease-specific curated or validated outcome measure for this specific patient 
group. 
  
MATERIALS AND METHODS 
Developing CDEs for mitochondrial disorders was challenging due to the heterogeneity of 
potential disease symptoms that may develop. CDEs reviewed and selected for this project 
focused on features within and outside the domain of clinical neurology, spanning almost all 
organ systems. Selected CDEs would benefit the majority of individuals with mitochondrial 
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disorders and would be linked to appropriate measures to objectively assess disease severity and 
progression. Therefore, the Mitochondrial Disease CDE WG was divided into nine subgroups to 
focus on identifying and defining data elements in the following domains: Biomarkers; 
Cognitive/ Behavioral/ Psychological; Endocrinology/ Diabetes/ Gastrointestinal/ Nutrition; 
Exercise Physiology; Genetics; Imaging; Neurological Assessments; Patient Reported Outcomes/ 
Quality of Life; and Vision. Bi-weekly teleconferences for each WG for a period of six months 
were held until project completion. In order to remain consistent with the overall CDE format, 
the WG recommendations were classified into one of four categories: 
Core: A data element for recording essential information applicable to any mitochondrial disease 
study including therapeutic areas and study designs. Consistent with all NINDS disease-specific 
CDE sets, the Core Mito CDEs are a small subset of all available CDEs that are the most specific 
and valuable for all Mito studies. 
Supplemental – Highly Recommended: A data element which is recommended for use whenever 
applicable, based on certain conditions or clinical study designs. In most cases, these have been 
used and validated with strong psychometrics for use in mitochondrial disease, and are 
considered essential for clinical research studies by experts in the field. 
Supplemental: A data element which has some evidence of validity and is commonly collected in 
clinical studies in mitochondrial disease. Use depends upon the study design, protocol or type of 
research involved.  
Exploratory: A data element that could be emerging or that requires further validation in target 
populations, but may fill current gaps in the CDEs and/or substitute for an existing CDE with 
additional evidence. 
Pre-existing individual CDEs selected for other clinically similar disease phenotypes were 
included and other appropriate instruments were added when available. All were critically 
evaluated for appropriateness to mitochondrial disorders even if historical reliability and validity 
was accepted for other diseases. Statistical analysis was not performed at this time, as this is not 
applicable for the development and initial description of the Mito CDEs. In the future, statistical 
analyses will help determine if these CDEs can be specifically validated for mitochondrial 
diseases. The draft Mito CDEs were posted on the NINDS CDE website for public review from 
November 20, 2014 to January 16, 2015. The final Version 1.0 Mito CDEs were posted on 
February 25, 2015, following the incorporation of comments received from public review from 
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the mitochondrial clinical research community. The process describing the formation of the 
CDEs is available on the CDE website at 
https://www.commondataelements.ninds.nih.gov/CDEStandard.aspx. Figure 1 illustrates the 
mitochondrial CDE development process.  
  
RESULTS 
The nine WGs reviewed a total of 153 CRFs and instruments (56 for Cognitive/ Behavioral/ 
Psychological outcomes, 17 for Neurological Assessments, 28 for Patient Reported 
Outcomes/QoL, 41 for Exercise Physiology, and 11 for Endocrinology/ Diabetes/ GI/ Nutrition). 
This resulted in a library of 120 CRF and instruments recommendations divided into 4 domains 
including: 1) Participant History and Family History, 2) Participant Characteristics, 3) 
Assessment and Examinations, and 4) Outcomes and Endpoints. Recommendations from the 
Mito CDE project posted on the NINDS CDE website contain a summary of each instrument, its 
recommended use, and comparative strengths and weaknesses. Although the CDEs have been 
developed for the unique purpose of advancing mitochondrial medicine clinical research, several 
of the CRFs reviewed include ones used on a clinical basis for patient care purposes. The WGs 
did not develop the CDEs with the intention of utilizing these in clinical care, and further 
consideration about care guidelines (i.e., diagnostic algorithm, nutrition/exercise guidelines, etc) 
would exceed the scope of this paper.   
Core elements for the mitochondrial disorders included one general core element common to all 
other disorders reviewed for CDEs, namely the demographic patient/participant characteristics. 
The WGs did not find any element that was strongly representative of mitochondrial disorders 
and thus no additional core elements specifically required for all mitochondrial disorders were 
selected. Of the remaining recommended categories, 17% of the elements assessed were 
categorized as Supplemental-Highly Recommended, 75% as Supplemental, and 8% as 
Exploratory. The Highlight Summary Document is available in table format on the CDE 
webpage 
(https://www.commondataelements.ninds.nih.gov/Doc/MITO/Mitochondrial_Disease_CDE_Hig
hlight_Summary.pdf). There was no Core elements recommended due to lack of validation in 
mitochondrial disease cohorts. The Supplemental – Highly Recommended instruments (for 
specific disease conditions or types of study) included: Anthropometrics-Vital Signs, Apathy 
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Evaluation Scale, Automated Self-administered 24-hour Dietary Recall (ASA 24),  Barry 
Albright Dystonia Scale (BADS), Behavior Rating Inventory of Executive Function (BRIEF), 
Behavior Rating Inventory of Executive Function-Preschool Version (BRIEF-P), Conners 3, 
Diabetes-Related Medical History, Echocardiogram, Genetic Testing Short Form, Genetic 
Testing Clinical Diagnostics, Laboratory Tests and Non-Imaging Diagnostics (Diabetes), 
Maximal Exercise Test, Modified Hammersmith Functional Motor Scale (MHFMS-SMA, 
MHFMS), Peabody Development Motor Scale II, Pediatric Quality of Life Inventory (PEDSQL), 
Pulmonary Function, Scale for the Assessment and Rating of Ataxia (SARA), Sub-Maximal 
Exercise Test, Test of Variable Attention (TOVA), The Borg Scale of Perceived Exertion, 
Vineland Adaptive Behavior Scales, 2nd Ed., World Health Organization Quality of Life 
Assessment (WHOQOL). Table 1 summarizes the CDEs  based on Working Group category and 
level of recommended use (Core, Supplemental – Highly Recommended, Supplemental, 
Exploratory).  
  
Navigating the NINDS Mito CDE website 
The Mito CDEs are available at the NINDS CDE Mito Website.  A brief summary of the project, 
along with documents to assist in starting a study, are presented on the Data Standards tab of the 
Mito disease page. The Mito CDE recommendations are grouped by Domains and Sub-Domains 
below this introductory information. CRFs and their accompanying CDEs (listed as “CDE 
Details” on the website) can be downloaded as needed. Users are also able to learn more about 
the CDE project by navigating to the Learn menu at the top right of the page, where tutorials, a 
project overview and definitions are available 
(https://www.commondataelements.ninds.nih.gov/MITO.aspx#tab=Data_Standards). 
 
WG Results Summary 
Biomarkers 
The Mito Biomarkers WG found that none of the reported biomarkers are consistently altered, 
nor have been used to assess mitochondrial disease in every study. For example, elevated lactic 
acid, commonly considered to be a biomarker of mitochondrial disease, is not consistently  
elevated in blood across all mitochondrial diseases, especially when only a single organ is 
involved (e.g., the eye in Leber’s hereditary optic neuropathy). Conversely, lactate levels in bold 
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are frequently elevated in many pediatric mitochondrial diseases where the oxidative 
phosphorylation deficiency is often both severe and widespread. The WG also considered some 
parameters that are absolutely essential, but in only one disease. For example, thymidine and 
deoxyuridine levels along with thymidine phosphorylase enzymology are only useful in 
Mitochondrial neurogastrointestinal encephalopathy (MNGIE) syndrome, a very rare genetic 
disease caused by thymidine phosphorylase deficiency. The WG found the task of defining an 
extensive list of “specific” parameters difficult because of the high, and steadily increasing, 
number of different causes of mitochondrial diseases as well as a growing list of new biomarkers 
(e.g. FGF-21, GDF-15) (Suomalainen 2013; Yatsuga et al 2015). As a result, all biomarkers 
recommended by the WG are classified as Supplemental and were fully defined in a guidelines 
document to assist researchers in their studies. 
  
Cognitive/Behavioral/Psychological Outcomes 
A broad range of clinical phenotypes is observed in both children and adults with mitochondrial 
disorders, with symptoms that may progressively develop and wax and wane in severity over the 
course of the entire lifespan. As a result, the instruments recommended vary according to age 
and the specific type of disorder. Furthermore, the scoring and use of the instruments may vary 
based on the clinical history. Modification of the scoring system for some of the instruments may 
be recommended to achieve higher sensitivity of symptom assessment (i.e., use of raw scores vs. 
standard scores). The WG also suggested considering the intended use of the instrument in any 
given study, such as a natural history to study changes over time in a clinical trial. The WG 
recommends selecting individual components of the larger tools to study in clinical trials. An 
example of this would be the use of memory or executive functioning subsets of the NIH 
Toolbox instead of using the whole instrument. While choosing instrument recommendations, 
the group did not encounter any tools unique to individuals with mitochondrial disorders and 
therefore there are no validated tools available for this population of patients. 
  
Endocrinology/Diabetes/Gastrointestinal/Nutrition 
Diabetes mellitus, abnormal growth, gastrointestinal (GI) problems and nutrition-related 
concerns are important features of mitochondrial disease. This WG developed instruments 
focused on diabetes mellitus, anthropometric measurements, GI symptoms and nutritional 
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assessment, including diet and use of dietary supplements. The WG acknowledged that the 
diversity of current approaches to treatment of mitochondrial disease in general and particular 
subtypes in particular, including nutrition and supplements, leads to difficulties in standardized 
documentation to enable ready evaluation of their potential impact. Given their importance to the 
overall health of affected individuals, careful assessment and study of endocrine and GI-related 
health conditions was recommended. The Office of Dietary Supplements at NIH organized a 
community meeting and subsequent working group dedicated to further investigation of the 
impact of nutritional interventions in primary mitochondrial diseases (Camp et al 2016).   
 
  
Exercise Physiology 
The Exercise Physiology WG focused on the areas of exercise intolerance, endurance, and 
exercise recommendations. Exercise intolerance is one of the most prevalent symptoms of 
mitochondrial disease, especially in adults with mitochondrial myopathy. The WG did not 
address clinical recommendations on exercise as a treatment, but rather focused on 
recommended instruments to measure fatigue, exercise intolerance, and ability to exercise.  The 
Borg Scale of Perceived Exertion, The Newcastle Pediatric Mitochondrial Disease Scale 
(NPMDS), echocardiogram, electrocardiogram, maximum and submaximum exercise testing, 
and Pulmonary Function Testing were recommended as Supplemental– Highly Recommended 
tests. The 6 Minute Walk Test is widely used in clinical trials as a reflection of overall exercise 
capacity, and was considered to be a Supplemental test for mitochondrial disease evaluation as 
determined by evidence available to the Exercise Physiology WG.  
 
Genetics 
Inclusion in clinical trials increasingly requires the establishment of a known pathogenic 
mutation in a mitochondrial disease-associated gene using standard criteria.  Thus, establishing 
an accurate molecular diagnosis is important for clinical trial participation. The Genetics WG 
made a clear distinction between genetic testing for clinical purposes (i.e., in a CLIA-certified 
diagnostic laboratory) versus on a research basis. Genetic testing should be performed in an 
experienced laboratory with clearly defined analytic methodology.  Depending on clinical 
presentation and exact methodology used, such analyses may include next generation sequencing 
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of relevant nuclear genes in the form of gene panels and/or the exome, genome-wide SNP 
microarray analysis to detect nuclear chromosomal copy number alterations, and mitochondrial 
genome next generation sequencing to detect low level heteroplasmy for mitochondrial point 
mutations or small copy number alterations,  real-time quantitative PCR to detect large mtDNA 
deletions and duplications, and/or quantitative PCR to measure mtDNA genome content in 
relevant tissues. The specific DNA variant identified should be documented relative to a 
reference sequence and using established ACMG guidelines (Richards et al 2015).  If available, 
previous publications reporting pathogenicity of the variant should be cited (MacArthur et al 
2014). Often this is performed through literature or database searches, using online tools such as 
MITOMAP (Lott et al 2013) and ClinVar (Harrison et al 2016). If the variant is novel, and 
prediction programs such as PolyPhen and SIFT are used, the specific versions and tools should 
be cited because, occasionally, multiple programs may issue conflicting predictions.  Segregation 
studies within the family should be performed to confirm expected inheritance patterns.  
Biochemical studies should be performed in subjects’ blood, urine, cells, and/or tissue to confirm 
mitochondrial dysfunction type and degree, as needed or appropriate.  In certain instances, in 
vitro cellular and/or animal model experiments might be needed to further evaluate the 
pathogenicity of novel variants of unknown significance.  
  
Imaging 
The Imaging WG aimed to establish a data form that would be all-inclusive, ideally serving as a 
reference guide for what imaging data points might be useful to collect when researching 
mitochondrial disorders. While recommending many existing Imaging CDEs, the WG 
highlighted several variables in the Mito Imaging CRF that are characteristic of, although not 
exclusive, to mitochondrial disorders. The most notable elements are the involvement of deep 
gray nuclei, white matter tracts, and myelination pattern. 
  
Neurological Assessments 
The spectrum of clinical manifestations of mitochondrial diseases spans every component of the 
nervous system (i.e., brain, spinal cord, peripheral nerves, autonomic nervous system, and 
muscle). The scales to capture a specific neurological disability vary in regards to their universal 
acceptance, sensitivity, complexity, and time-for-completion. As the CDEs are a project of the 
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NINDS, and several other neurological diseases already had completed CDEs available for 
review, the Mito CDE WGs had the benefit of reviewing CDEs for clinically overlapping 
disorders including: Friedreich ataxia, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, 
Duchenne muscular dystrophy, stroke, spinal cord injury, and Huntington and Parkinson 
diseases. As many of the progressive neurological disorders have overlapping clinical symptoms, 
as well as secondary mitochondrial dysfunction contributing to their pathophysiology, many of 
the CRFs from these other neurological diseases were potentially applicable as Mito CDEs.   
 
The WG recommended that the choice of scales for a specific patient or study should include 
those that best measure function for the identified disability, and possibly scales that would 
measure function from the pre-symptomatic state for expected disabilities that could be predicted 
to develop by the patient’s clinical diagnosis or genotype. The WG aimed to provide a battery of 
neurological tests that would capture small changes in cognitive function, development, motor 
weakness (muscle and nerve), coordination and movement disorders (e.g., ataxia, dystonia). 
  
Patient Reported Outcomes/Quality of Life (PRO/QoL) 
The PRO/QoL WG found no QoL CDEs to be essential and thus no instruments were classified 
as Core. The recommended instruments had no differential application to subtypes of 
mitochondrial disease. However, the scales are often dependent on subject age for 
administration, and some are better suited for subjects with higher cognitive skills. Among 
several available QoL scales, the WG determined two that should be Supplemental – Highly 
Recommended: the World Health Organization Quality of Life Assessment (WHOQOL) and the 
Pediatric Quality of Life Inventory (PEDSQL). Due to overall limitations, lack of a validated 
instrument, and the heterogeneity of mitochondrial diseases, it was difficult to define universal 
CDEs for QoL within mitochondrial diseases. 
  
Vision 
The Vision WG recommendations were made to be applicable to all types of mitochondrial 
disease. Adequate training of physicians and technicians performing various ophthalmological 
tests with ongoing quality control were deemed essential. Several platforms were identified that 
are available for visual field perimetry and optical coherence tomography (OCT) imaging. The 
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chosen tests will largely depend on the preference of the investigators and the specific facilities 
available in their respective study centers. The WG emphasized the need to ensure that the same 
platform and acquisition protocol are used across all the centers involved in a given study to 
allow for direct comparison and/or grouping of data at study conclusion. For visual 
electrophysiology, it was deemed imperative that testing be performed to incorporate the ISCEV 
(International Society for Clinical Electrophysiology of Vision) standards. 
  
DISCUSSION 
The development of CDEs to facilitate mitochondrial disease research is timely, in view of the 
improvements and implementation of widespread genetic testing that has led to genetically-
defined mitochondrial diseases and large patient cohorts. In addition, there has been a recent 
increase in candidate therapies proposed for these currently incurable disorders, with promising 
results in several preclinical studies in cell and animal models (Rahman 2015; Nightingale et al 
2016). The CDE project is an international collaborative effort involving the many key 
stakeholders in mitochondrial medicine, including clinicians, translational and basic researchers, 
industry partners, patient advocacy groups, and the NIH. The breadth of our collaborators is a 
testament to the interest and need for these shared research tools to move the mitochondrial 
medicine field forward. 
 
The WGs reviewed a total of 153 CRFs and instruments for the possible inclusion in the Mito 
CDEs. Interestingly, and perhaps not surprisingly, the WGs did not find a single Core data 
element; demonstrating once again the challenges for clinical research in mitochondrial diseases.  
The CDEs were categorized based on their prior use in both mitochondrial diseases or similar 
disorders and whether they were scientifically robust and clinically significant. Together, these 
CDEs cover almost the entire disease spectrum of these complex multi-systemic disorders, and 
have been developed with the intention of providing a publicly available resource to facilitate the 
design of protocols for any clinical study relating to mitochondrial disease. Some caveats should 
be noted. The Mito CDEs are suggested guidelines rather than definitive requirements for future 
study protocols and are not intended for use in clinical patient care. Clinical study design should 
take into account the specific diseases (considering both genotype and phenotype) under study, 
age group of affected patients and nature of the intervention, and incorporate the most relevant 
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CDEs, in addition to any other outcome measures that the researchers consider appropriate. The 
Mito CDE recommendations are based on current knowledge of a rapidly expanding and 
changing group of heterogeneous disorders, and it is anticipated that, while having a stable set of 
essential elements, these will be dynamic and need to be updated as the field advances and 
specific instruments become validated for use in mitochondrial disease. The NINDS has 
developed oversight committees that will review feedback from the community and adjust the 
CDEs periodically, as needed.  
 
The availability of a global set of CDEs addressing many of the multi-systemic features should 
help serve as a starting place to harmonize data collection and ultimately enable the combination 
and comparison of outcomes of clinical studies in mitochondrial diseases. Given the diversity 
and spectrum of clinical manifestations seen in these disorders, selection of outcome measures 
for clinical research presents a unique challenge. These difficulties are further compounded by 
the rarity of each individual genetic entity of this group of disorders, challenges to robust study 
design, and need for substantive funding. It is thus imperative that patient support groups, 
together with mitochondrial disease clinician networks and research consortia, partner with 
industry and the FDA to validate these measures, recently discussed at a Critical Path Innovation 
Meeting (CPIM) 
(https://ods.od.nih.gov/attachments/CriticalPathInnovationMeetingSummary.pdf). The 
international collaboration on this CDE project has continued to be fruitful, with projects 
ongoing to harmonize global patient registries, to validate patient-centered outcome measures, 
and to create mitochondrial disease specific outcome measures inspired by the CDEs reviewed in 
this project. 
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Domain Instrument or CDEs 
  Core Supplemental - Highly 
Recommended 
Supplemental Exploratory 
Demographics General Core (e.g., 
Gender, Birth Date, 
Race) 
      
General Health History   Diabetes-Related 
Medical History 
Dietary Supplements, Reproductive and 
Hormonal History 
  
Physical Examinations   Automated Self-
Administered 24-hour 
Dietary Recall (ASA 24) 
Mitochondrial and Gastrointestinal 
Diseases Assessment 
  
Imaging Diagnostics     Brain Magnetic Resonance Imaging 
(MRI), Brain Perfusion Magnetic 
Resonance Imaging, Cardiac Magnetic 
Resonance Imaging (MRI), Imaging – 
Mitochondrial Disease, 
Electrocardiogram (ECG), Imaging 
Guidelines and Definition 
Phosphorus Magnetic 
Resonance 
Spectroscopy 
(31PMRS), Two 
Dimensional Speckle 
Tracking 
Echocardiography 
Imaging 
Laboratory 
Tests/Biomarkers 
  Laboratory Tests and 
Non-Imaging 
Diagnostics (Diabetes) 
Biomarkers Guidelines Mitochondrial 
Disease, Biomarkers in Mitochondrial 
Disease 
  
Table Click here to download Table Table 1. CDE based on Working Group and
Recommendation.docx
Domain Instrument or CDEs 
  Core Supplemental - Highly 
Recommended 
Supplemental Exploratory 
Genetics   Genetic Testing Short 
Form, Genetics Testing 
Clinical Diagnostics 
Genetic Testing Short Form, Genetics 
Testing Clinical Diagnostics 
  
Non-Imaging 
Diagnostics 
  Echocardiogram Holter Examination   
Vision     Vision Mitochondria Disease OCT 
Guidelines, Vision Mitochondrial 
Disease Test Guidelines, Vision 
Mitochondrial Disease Visual Fields 
Guidelines 
  
Vital Signs and Other 
Body Measures 
    Vital Signs   
Academic Achievement      American National Adult Reading Test 
(AmNART) 
  
Adaptive   Vineland Adaptive 
Behavior Scales 
Adaptive Behavior Assessment Scale 
(ABAS-II), Delis Kaplan Executive 
Functioning System (DKEFS), 2nd Ed. 
(Vineland-II) 
  
Domain Instrument or CDEs 
  Core Supplemental - Highly 
Recommended 
Supplemental Exploratory 
Attention   Conners III Delis Kaplan Executive Function System 
(DKEFS), National Institutes of Health 
(NIH) Toolbox, Test of Variable 
Attention (TOVA) 
  
Ataxia and Performance 
Measures 
  Scale for the 
Assessment and Rating 
of Ataxia 
International Cooperative Ataxia Rating 
Scale (ICARS) 
  
Cognitive     Automated Neuropsychological 
Assessment Metrics (ANAM), Axon 
Sports Computerized Cognitive 
Assessment, Brief Test of Adult 
Cognition by Telephone (BTACT), 
Cambridge Cognitive Assessment 
Revised (CAMCOG-R) 
  
Dementia     Informant Questionnaire on Cognitive 
Decline in the Elderly (IQCODE), 
Montreal Cognitive Assessment (MoCA) 
  
Domain Instrument or CDEs 
  Core Supplemental - Highly 
Recommended 
Supplemental Exploratory 
Emotional/Behavioral   Apathy Evaluation 
Scale 
ALS Depression Inventory (ADI-12), 
Apathy Scale (AS), Autism Diagnostic 
Interview (ADI), Autism Diagnostic 
Observation Schedule (ADOS), Beck 
Anxiety Inventory (BAI), Brief Infant 
Toddler Social Emotional Assessment 
(BITSEA), Brief Psychiatric Rating Scale 
(BPRS), Cambridge Behavioral Inventory 
– Revised, Center for Epidemiological 
Studies – Depression Scale (CES-D), 
Child Behavior Checklist (CBCL), Child 
Depression Inventory (CDI), Children 
Depression Inventory – 2 (CDI-2), 
Columbia Suicide Severity Rating Scale 
(CSSRS), Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5), 
Generalized Anxiety Disorder (GAD-7), 
Hamilton Anxiety Rating Scale (HAM-A), 
Hamilton Depression Rating Scale 
(HDRS), Irritability Scale, Modified Overt 
Aggression Scale (MOAS), Montgomery- 
Åsberg Depression Scale (MADRS), 
Mood Disorder Questionnaire (MDQ), 
Problem Behaviours Assessment HD – 
Short Version (PBA-S), Social 
Responsiveness Scale (SRS) 
  
Executive Functioning    Adaptive Behavior 
Assessment System-II 
    
Domain Instrument or CDEs 
  Core Supplemental - Highly 
Recommended 
Supplemental Exploratory 
(ABAS-II) *, Behavior 
Rating Inventory of 
Executive Function 
(BRIEF) *, Behavior 
Rating Inventory of 
Executive Function – 
Preschool Version 
(BRIEF-P) * 
Motor/Physical 
Function 
  Borg Rating of 
Perceived Exertion 
(RPE) Scale, Modified 
Hammersmith 
Functional Motor Scale 
for Children with Spinal 
Muscular Atrophy 
(MHFMS-
SMA/MHFMS-Extend), 
Peabody 
Developmental Motor 
Scale II (PDMS-2), Barry 
Albright Dystonia Scale 
(BADS) 
6 Minute Walk Test, Physical Activity 
Questionnaire for Adolescents (PAQ-A), 
Beery-Buktenica Developmental Test of 
Visual-Motor Integration (Beery VMI), 
Burke-Fahn-Marsden Movement Scale 
(BFMMS), Newcastle Mitochondrial 
Disease Adult Scale, Newcastle Pediatric 
Mitochondrial Disease Scale (NPMDS), 
Unified Dystonia Rating Scale (UDRS) 
2 Minute Walk Test, 
Alberta Infant Motor 
Scale, Gross Motor 
Function Measure 
(GMFM-88, GMFM-66), 
Motor Function 
Measure (MFM), 
Physical and 
Neurological 
Examination for Subtle 
Signs (PANESS), 
International Pediatric 
Mitochondrial Disease 
Score (IPMDS) 
Domain Instrument or CDEs 
  Core Supplemental - Highly 
Recommended 
Supplemental Exploratory 
Intellectual Functioning     Kaufman Assessment Battery for 
Children, Leiter International 
Performance Scale-3 (Leiter-3), 
Reynolds Intellectual Assessment Scale 
(RIAS), Wechsler Abbreviated Scale of 
Intelligence Scale – Fourth Edition 
(WAIS-IV), Wechsler Intelligence Scale 
for Children-IV (WISC-IV), Wechsler 
Preschool and Primary Scale of 
Intelligence (WPPSI-III) 
  
Language     Boston Diagnostic Aphasia Exam (BDAE-
III), Boston Naming Test (BNT) – 30-item 
version, Clinical Evaluation of Language 
Fundamentals (CLEF-4), Comprehensive 
Assessment of Spoken Language (CASL), 
Expressive One-Word Picture 
Vocabulary Test, New Reynell 
Developmental Language Scale (NRDLS), 
Peabody Picture Vocabulary Test 4th 
Edition (PPVT-4), Preschool Language 
Scales-Fifth Edition (PLS-5) 
  
Memory   Amyotrophic Lateral 
Sclerosis Depression 
Inventory-12 (ADI-12) * 
Memory Assessment Scale, Summary of 
Recommendations for Global Outcome, 
Wechsler Memory Scale IV (WMS-IV) 
  
Muscle Strength Testing     Manual Muscle Testing-Using the 
Medical Research Council Muscle 
Grading Scale, Maximum Voluntary 
Isometric Contraction Testing (MVICT) 
  
Domain Instrument or CDEs 
  Core Supplemental - Highly 
Recommended 
Supplemental Exploratory 
Neuropsychological 
Testing 
    Bayley Scales of Infant Development 
(Bayley III, BSID) 
  
Pulmonary Function 
Testing/Respiratory 
Status  
  Pulmonary Function     
Quality of Life    Pediatric Quality of Life 
Inventory (PEDSQL), 
World Health 
Organization Quality of 
Life Assessment 
(WHOQOL-BREF) 
Child and Adolescent Scale of 
Environment (CASE), Child and 
Adolescent Scale of Participation, Craig 
Handicap and Assessment Reporting 
Technique (CHART-SF) – Interview 
version, Craig Handicap and Assessment 
Reporting Technique (CHART-SF) Paper 
version, Quality of Life in Neurological 
Disorders (Neuro-QOL), Short Form 36-
Item Health Survey (SF-36) 
EurQol-5 Dimension 
Questionnaire, Family 
Strain Questionnaire 
Assessment of 
Preschooled Children’s 
Participation), Pediatric 
Quality of Life 
Inventory 
Multidimensional 
Fatigue Scale 
Visual-Spatial 
Processing 
    Judgment of Line Orientation (Benton 
JLO) 
  
Table 1. Common Data Elements based on Working Group and Level of recommendation (Core, Supplemental  - Highly Recommended, 
Supplemental, Exploratory). 
DIVISION INTO 9 WORKING GROUPS for: 
Biomarkers; Cognitive/ Behavioral/ Psychological; Endocrinology/ Diabetes/ 
Gastrointestinal/ Nutrition; Exercise Physiology; Genetics; Imaging; Neurological 
Assessments; Patient Reported Outcomes/ Quality of Life; and Vision
Bi-weekly teleconferences for each WG for six months 
Each WG reviewed current data collection forms,  case report forms, 
published literature, natural history studies, clinical trials, biomarker studies, 
and CDEs for related disorders
Classify elements into 4 categories:
CDEs for Mitochondrial Disease posted on the NINDS CDE Website:
February 2015
Internal WG Review (October 2014) and 
Public Review from Community (November-December 2014) 
Figure 1. Flowchart illustrating the Mito CDE development process. 
IDENTIFY INTERNATIONAL EXPERTS IN MITOCHONDRIAL DISEASE
Core Supplemental – Highly 
Recommended
Supplemental Exploratory
Figure Click here to download Figure Figure 1. Flowchart of
Mito CDE development process.pptx
